Hebei Key Laboratory of Preventive Veterinary Medicine, College of Animal Science and Technology, Hebei Normal University of Science and Technology, Qinhuangdao, 066004, China.
College of Veterinary Medicine, Northeast Agricultural University, Harbin, 150030, China.
Appl Microbiol Biotechnol. 2024 Mar 2;108(1):248. doi: 10.1007/s00253-023-12989-0.
Porcine epidemic diarrhea (PED) caused by porcine epidemic diarrhea virus (PEDV), is an acute and highly infectious disease, resulting in substantial economic losses in the pig industry. Given that PEDV primarily infects the mucosal surfaces of the intestinal tract, it is crucial to improve the mucosal immunity to prevent viral invasion. Lactic acid bacteria (LAB) oral vaccines offer unique advantages and potential applications in combatting mucosal infectious diseases, making them an ideal approach for controlling PED outbreaks. However, traditional LAB oral vaccines use plasmids for exogenous protein expression and antibiotic genes as selection markers. Antibiotic genes can be diffused through transposition, transfer, or homologous recombination, resulting in the generation of drug-resistant strains. To overcome these issues, genome-editing technology has been developed to achieve gene expression in LAB genomes. In this study, we used the CRISPR-NCas9 system to integrate the PEDV S1 gene into the genome of alanine racemase-deficient Lactobacillus paracasei △Alr HLJ-27 (L. paracasei △Alr HLJ-27) at the thymidylate synthase (thyA) site, generating a strain, S1/△Alr HLJ-27. We conducted immunization assays in mice and piglets to evaluate the level of immune response and evaluated its protective effect against PEDV through challenge tests in piglets. Oral administration of the strain S1/△Alr HLJ-27 in mice and piglets elicited mucosal, humoral, and cellular immune responses. The strain also exhibited a certain level of resistance against PEDV infection in piglets. These results demonstrate the potential of S1/△Alr HLJ-27 as an oral vaccine candidate for PEDV control. KEY POINTS: • A strain S1/△Alr HLJ-27 was constructed as the candidate for an oral vaccine. • Immunogenicity response and challenge test was carried out to analyze the ability of the strain. • The strain S1/△Alr HLJ-27 could provide protection for piglets to a certain extent.
猪流行性腹泻(PED)由猪流行性腹泻病毒(PEDV)引起,是一种急性、高度传染性疾病,给养猪业造成了巨大的经济损失。由于 PEDV 主要感染肠道的黏膜表面,因此提高黏膜免疫力以防止病毒入侵至关重要。乳酸菌(LAB)口服疫苗在防治黏膜感染性疾病方面具有独特的优势和潜力,是控制 PED 爆发的理想方法。然而,传统的 LAB 口服疫苗使用质粒进行外源蛋白表达和抗生素基因作为选择标记。抗生素基因可以通过转座、转移或同源重组扩散,导致耐药菌株的产生。为了解决这些问题,已经开发了基因组编辑技术来实现 LAB 基因组中的基因表达。在这项研究中,我们使用 CRISPR-NCas9 系统将 PEDV S1 基因整合到丙氨酸消旋酶缺陷型副干酪乳杆菌△Alr HLJ-27(L. paracasei△Alr HLJ-27)的胸苷酸合酶(thyA)位点基因组中,构建了一株 S1/△Alr HLJ-27 菌株。我们在小鼠和仔猪中进行了免疫试验,评估了免疫反应水平,并通过仔猪攻毒试验评估了其对 PEDV 的保护作用。该菌株在小鼠和仔猪中的口服给药可诱导黏膜、体液和细胞免疫反应。该菌株在仔猪中对 PEDV 感染也具有一定的抗性。这些结果表明,S1/△Alr HLJ-27 作为 PEDV 控制的口服疫苗候选株具有潜力。 要点: • 构建了一株 S1/△Alr HLJ-27 作为口服疫苗候选株。 • 进行了免疫原性反应和攻毒试验来分析该菌株的能力。 • S1/△Alr HLJ-27 株在一定程度上能够为仔猪提供保护。